TRIL

Trillium Therapeutics Inc.

Price

return (12m)

p/e

31.67

p/bv

0.00

DIVIDEND YIELD

0.00%

TRIL price

Trillium Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment TRIL

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals TRIL

Valuation

P/E

31.67

Sector -3.73

Industry -3.73

P/BV

0.00

Sector 2.16

Industry 2.16

P/Revenue (PSR)

23,970.07

Sector 2.15

Industry 2.15

EV/EBITDA

Sector -221.18

Industry -221.18

EV/EBIT

Sector -47.52

Industry -47.52

P/EBITDA

31.88

Sector -21.48

Industry -21.48

P/EBIT

31.95

Sector -31.80

Industry -31.80

P/Total Assets

Sector 1.26

Industry 1.26

P/Net Current Assets

Sector -11.06

Industry -11.06

P/Working Capital

Sector -190.98

Industry -190.98

EPS

0.63

Sector -1.77

Industry -1.77

BVPS

Sector 2.05

Industry 2.05

Efficiency

Gross Margin

76.74%

Sector 41.11%

Industry 41.11%

EBITDA Margin

-194,510.00%

Sector -17,824.00%

Industry -17,824.00%

EBIT Margin

-194,990.00%

Sector -4,221,656.00%

Industry -4,221,656.00%

Operating Margin

-100.00%

Sector -34.64%

Industry -34.64%

Net Profit Margins

100.00%

Sector -35.45%

Industry -35.45%

Asset Turnover

Sector 0.03

Industry 0.03

Profitability

ROE

0.00%

Sector -56.40%

Industry -56.40%

ROA

0.00%

Sector -59.80%

Industry -59.80%

ROIC

Sector -2,338.86%

Industry -2,338.86%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

Sector 2.89

Industry 2.89

Net Debt / EBITDA

Sector -14,697,933.03

Industry -14,697,933.03

Net Debt / EBIT

Sector -8.34

Industry -8.34

Net Debt / Equity

Sector -34,400.71

Industry -34,400.71

Gross Debt / Equity

Sector -0.85

Industry -0.85

Equity/Assets

Sector 0.46

Industry 0.46

Liabilities/Assets

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

10.17%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

Fundamentals TRIL

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
TRIL Trillium Therapeutics Inc.	$0.00	-	0.00%	31.67	0.00	0.00%	100.00%
JNJ Johnson & Johnson	$275.23	58.90%	1.90%	31.48	7.79	24.76%	21.48%
PFE Pfizer Inc.	$28.45	22.40%	6.01%	37.36	1.91	5.11%	6.86%
ABBV AbbVie Inc.	$256.46	24.50%	2.66%	72.11	-76.75	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.60	-9.87%	3.97%	11.43	6.07	53.11%	35.32%
MRK Merck & Co. Inc.	$150.33	84.41%	2.24%	116.76	8.81	7.55%	4.76%
AZN AstraZeneca PLC	$162.70	1.99%	1.98%	19.30	4.97	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$66.82	48.47%	3.75%	14.74	6.13	41.55%	18.85%
ZTS Zoetis Inc.	$75.81	-49.60%	2.76%	11.95	10.04	84.02%	27.77%
AMGN Amgen Inc.	$438.54	60.04%	2.25%	26.93	20.14	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$827.72	48.81%	0.44%	19.82	2.71	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$110.19	47.06%	0.00%	31.19	89.88	288.13%	24.86%
MCK McKesson Corporation	$907.99	32.77%	0.36%	20.52	-28.15	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$546.12	37.87%	0.00%	31.75	6.91	21.76%	35.00%
CAH Cardinal Health Inc.	$247.18	67.38%	0.83%	37.62	-21.79	-57.93%	0.62%
ARGX argenx SE	$1,038.19	43.79%	0.00%	3.11	3.48	112.18%	44.41%
HRMY Harmony Biosciences Holdings Inc.	$42.25	17.39%	0.00%	13.47	2.44	18.14%	18.88%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

TRIL Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Trillium Therapeutics

Trillium Therapeutics Inc.

Average Investor10 user rating

4.0 (0 people)

United States

22 years

Founded: 2004

2009

Time since IPO - 17 years

33

Employees

Trillium Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $2.06 billion, with shareholders equity totaling $-.

The company employs approximately 33 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Trillium Therapeutics Inc. reported $86.00 Thousand in revenue, generating net income of $65.08 million.

Key financial metrics include a P/E ratio of 31.67, a price-to-book (P/B) ratio of 0.00, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker TRIL.

Market cap

$2.06 billion

Net worth

Assets

Total Shares Outstanding

103.78 million

103,782,000

Average Daily Trading Volume

$1.51 Thousand

$1,505.90

Sector

Health Care

Industry

Biotechnology

TRIL

TRIL revenue and profits

Financial Results TRIL

DRAG THE FRAME TO SEE MORE DATA

TRIL cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$907.99 30,94% (12M)

P/E

20.52

0.36%

ROE

-137.16%

P/BV

-28.15

CAH - Cardinal Health

$247.18 66,58% (12M)

P/E

37.62

0.83%

ROE

-57.93%

P/BV

-21.79

JNJ - Johnson & Johnson

$275.23 58,01% (12M)

P/E

31.48

1.90%

ROE

24.76%

P/BV

7.79

ABBV - AbbVie

$256.46 26,15% (12M)

P/E

72.11

2.66%

ROE

-106.44%

P/BV

-76.75

MRK - Merck & Co.

$150.33 85,77% (12M)

P/E

116.76

2.24%

ROE

7.55%

P/BV

8.81

AZN - AstraZeneca

$162.70 1,89% (12M)

P/E

19.30

1.98%

ROE

25.77%

P/BV

4.97

PFE - Pfizer

$28.45 24,05% (12M)

P/E

37.36

6.01%

ROE

5.11%

P/BV

1.91

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$907.99 30,94% (12 M)

P/L

20.52

0.36%

ROE

-137.16%

P/VP

-28.15

CAH - Cardinal Health

$247.18 66,58% (12 M)

P/L

37.62

0.83%

ROE

-57.93%

P/VP

-21.79

JNJ - Johnson & Johnson

$275.23 58,01% (12 M)

P/L

31.48

1.90%

ROE

24.76%

P/VP

7.79

ABBV - AbbVie

$256.46 26,15% (12 M)

P/L

72.11

2.66%

ROE

-106.44%

P/VP

-76.75

MRK - Merck & Co.

$150.33 85,77% (12 M)

P/L

116.76

2.24%

ROE

7.55%

P/VP

8.81

AZN - AstraZeneca

$162.70 1,89% (12 M)

P/L

19.30

1.98%

ROE

25.77%

P/VP

4.97

PFE - Pfizer

$28.45 24,05% (12 M)

P/L

37.36

6.01%

ROE

5.11%

P/VP

1.91

Frequently Asked Questions

What is the price of Trillium Therapeutics (TRIL) today?

A cotação de Trillium Therapeutics (TRIL) hoje está em US$ 0.00, com uma variação de 0% em relação ao último ano. A cotação de Trillium Therapeutics (TRIL) iniciou o ano negociando na casa dos US$ 20.13 e hoje está em US$ 0.00. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Trillium Therapeutics (TRIL) e dados de ações do Ibovespa e mercados internacionais.

Quando Trillium Therapeutics (TRIL) paga dividendos?

Trillium Therapeutics (TRIL) não distribuiu dividendos no último ano.

Is Trillium Therapeutics (TRIL) a good investment?

Atualmente, Trillium Therapeutics (TRIL) está cotada a US$ 0.00, com um P/L de 31.67, representando um desvio de 0% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 0 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Trillium Therapeutics (TRIL) stock?

Investir em ações de Trillium Therapeutics (TRIL) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Trillium Therapeutics (TRIL) yield today?

A rentabilidade de Trillium Therapeutics (TRIL) foi de 0.00% no último mês, 0.00% no último ano e 0.00% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Trillium Therapeutics (TRIL) hoje, o investimento total seria de US$ 0.00, com base na cotação atual de US$ 0.00.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 0.00
Em 5 anos: US$ 0.00
Em 10 anos: US$ 0.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

TRIL

Trillium Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment TRIL

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING TRIL WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Trillium Therapeutics

Trillium Therapeutics Inc.

United States

22 years

2009

33

PROFIT X PRICE TRIL

Financial Results TRIL

TRIL cash flow

Asset, Revenue and Profit Growth - TRIL

TRIL balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions